SCHEMBL4700628

SCHEMBL4700628

Cc1ncc2n1CCc1c-2n(C)c2ccc(OS(C)(=O)=O)cc12

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.36
MAOA P21397 3/20 0.36
KDM4E B2RXH2 3/20 0.36
HSD17B10 Q99714 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34
KMT2A Q03164 1/20 0.34
DRD2 P14416 2/20 0.33
DRD3 P35462 2/20 0.33
DRD1 P21728 1/20 0.33
DRD5 P21918 1/20 0.33
BCHE P06276 1/20 0.33
HTR5A P47898 2/20 0.32
PDE5A O76074 2/20 0.32
HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4698526 0.88 HSD17B10 (0.42) ACHEMAOAKDM4EHSD17B10ALDH1A1
SCHEMBL4699104 0.85 KDM4E (0.47) ACHEMAOAKDM4EHSD17B10MEN1
SCHEMBL4701769 0.84 KDM4E (0.46) ACHEMAOAKDM4EHSD17B10MEN1
SCHEMBL4702510 0.83 BAZ2B (0.41) ACHEMAOAKDM4EHSD17B10MEN1
SCHEMBL4699549 0.82 KDM4E (0.35) KDM4EHSD17B10MEN1ALDH1A1GAA
SCHEMBL4699059 0.79 MAPT (0.41) MAOAKDM4EALDH1A1MAPTHTR5A
SCHEMBL4699107 0.78 CYP1A2 (0.46) ACHEKDM4EMEN1ALDH1A1MAPT
SCHEMBL14425146 0.77 MAOA (0.46) MAOAALDH1A1MAPTHTR5APDE5A
SCHEMBL4702160 0.75 ALOX15 (0.41) ACHEMAOAKDM4EHSD17B10ALDH1A1
SCHEMBL14345923 0.73 KDM4E (0.44) ACHEMAOAKDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1390367-B1 DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE MACEF (FR) 2008-07-09 EP claimed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US claimed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US claimed
EP-1390367-B1 DIHYDROIMIDAZO 5,1-A -$G(b)-CARBOLINE DERIVATIVES, METHOD FOR PREPARING SAME AND USE THEREOF AS MEDICINE MACEF (FR) 2008-07-09 EP disclosed
US-7291627-B2 Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug MACEF (FR) 2007-11-06 US disclosed
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine MACEF (FR) 2006-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089372-A1 Dihydroimidazo[5,1-a]sg(b)-carboline derivatives, method for preparing same and use thereof as medicine GDI2, GDI1, CYP2A7 ACHE 1647/4885MAOA 524/4885KDM4E 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.